Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
September, 2024
September 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« Aug
Tanja Obradovic
Sep 10, 2024, 05:08 |
Blog
Tanja Obradovic: Two practice-changing trials of Keytruda within Presidential Symposium of ESMO24
Tanja Obradovic shared on LinkedIn: "ESMO 2024 will have two practice-changing trials of Keytruda (Pembrolizumab)…
Aug 31, 2024, 16:56 |
Blog
Tanja Obradovic: GI INNOVATION announced collaboration with Merck
Tanja Obradovic shared a post on LinkedIn: "Tackling challenges of cancer patients treatment after they progressed…
Aug 28, 2024, 17:09 |
Blog
Tanja Obradovic: Importance of vigilant toxicity monitoring
Tanja Obradovic shared a post on LinkedIn: "Importance of vigilant toxicity monitoring as well as early…
Aug 26, 2024, 21:42 |
Blog
Tanja Obradovic: Interesting update at ESMO 2024 on cancer-induced cachexia as PhII trial of ponsegromab
Tanja Obradovic posted on LinkedIn: “Interesting update will come at ESMO 2024 on possible option…
Aug 26, 2024, 21:24 |
Blog
Tanja Obradovic: Can we expect new EGFR TKI to surpass osimertinib in primary tumor and intracranial progression of NSCLC
Tanja Obradovic posted on LinkedIn: “Can we expect new EGFR TKI that can significantly surpass…
Aug 26, 2024, 20:20 |
Blog
Tanja Obradovic: Some points of interest from the Relativity-104 study
Tanja Obradovic shared on LinkedIn: "Opdualag, a cocktail of anti Lag-3 (relatlimab) and anti PD1…
Aug 26, 2024, 19:50 |
Blog
Tanja Obradovic reflects on first KRAS G12C mutation inhibitor approval
Tanja Obradovic posted on LinkedIn: "First KRAS G12C mutation inhibitor just got approval in China.…
Jul 6, 2024, 07:58 |
Drugs
Tanja Obradovic: Important lesson in development of the PDL-1 inhibitor just came in
Tanja Obradovic posted on LinkedIn: "Important lesson in the development of the PDL-1 inhibitor just…
Jul 6, 2024, 05:13 |
Insight
Tanja Obradovic: Choosing immunotherapy treatment for early resectable NSCLC
Tanja Obradovic shared on LinkedIn: "Choosing immunotherapy treatment options with PD(L)-1 inhibitors for early resectable non–small…
Jun 27, 2024, 02:53 |
Blog
Tanja Obradovic: Tempest Therapeutics just announced very good results from ongoing global clinical study with Amezalpat
Tanja Obradovic shared on LinkedIn: . “Are we to expect completely new mechanism of action…
1
2
3
4
5
6
All:
52
Posts:
1 - 10
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 3
Small Bowel Cancer: Symptoms & Causes, Types, Diagnosis and Treatment
Mikkael A. Sekeres, Candidate for Secretary of ASH
Paolo Tarantino: Top 10 Breast Cancer abstracts from ESMO2024
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 2
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube